Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ezetimibe/simvastatin

Allergan logo

Allergan stumps up $375m for bolt-on acquisitions

Firm has recently added two migraine drugs and Oculeve to its portfolio

- PMLiVE

Teva planning fresh offer for Mylan, say sources

Israeli firm has already made multiple informal bids

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

- PMLiVE

Generic Copaxone launches in US

Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Perrigo buys consumer health products from GSK

Several over-the-counter drug assets acquired at an undisclosed price

- PMLiVE

Perrigo warming to Mylan – at the right price

Perrigo has already rejected three prior bids

- PMLiVE

Endo buys Par for $8bn as M&A mania marches on

Acquisitionwill make Endo the fifth largest generics company in the US

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links